ROP linked to low haemoglobin
A retrospective study of 385 infants born at a mean gestational age of 26.4 weeks has shown that early, low-foetal haemoglobin (HbF) is associated with abnormal retinal neurovascular
Staff reporters1 min read
Ophthalmology News
Fatty acid supplements reduce ROP risk
A three-year clinical trial of enteral supplementation with fatty acids in premature infants has demonstrated a lowering of the risk of severe retinopathy of prematurity (ROP) by 50%. Three
Staff reporters1 min read
Glaukos expands services downunder
Following Glaukos’ acquisition of Avedro in 2019, the company is poised to introduce a range of new corneal health products into the Australian and New Zealand markets to complement its
Staff reporters2 min read
Trial of AI to predict DR
EviRed, a new artificial intelligence algorithm, is being ‘trained’ to predict the risk of diabetic retinopathy (DR) using modern imaging techniques. Professor Ramin Tadayoni at the University of
Staff reporters2 min read
Glaukos appoints new regional manager
Glaukos has appointed Neville White as regional business manager to support the rollout of its new corneal health business in Australasia. A former orthoptist in a busy ophthalmic practice in
Staff reporters1 min read
AMD exacerbates Covid complications
A study of 6,398 Covid-19-infected patients has shown that those with age-related macular degeneration (AMD) declined more rapidly, died at three times the rate of patients without AMD, and one in
Staff reporters1 min read
RANZCO NZ 2021: Balancing ophthalmology, life and today’s world
After the turbulent times of 2020, causing the postponement of the 2020 RANZCO NZ Branch Annual Scientific Meeting to 19-20 March this year, the NZ Branch executive is determined the 2021 meeting will proceed regardless of Covid-19 alert levels. To achieve this, a hybrid meeting system has been adop
Lesley Springall13 min read
Welcome to RANZCO NZ 2021
On behalf of the organising committee, I am pleased to invite and welcome you to the 2021 RANZCO New Zealand Branch Annual Scientific Meeting and the New Zealand Ophthalmic Nurses Group Meeting.
Dr Logan Robinson3 min read
Drops to replace anti-VEGF injections?
Exonate has begun a 48-patient clinical trial of its EXN407 drops for diabetic macular oedema (DMO), hoping they will eventually supplant intravitreal anti-vascular endothelial growth factor (VEGF) therapy injections.
Staff reporters1 min read
CERA researchers seek IRD patient views
Australian adults and parents of children with inherited retinal diseases (IRDs) are being asked to contribute their views to a new research survey on emerging gene therapies.
Staff reporters2 min read
Dr Kaliopy Matheos joins EI team
Dr Kaliopy Matheos has joined the Eye Institute team in Auckland. A New Zealand-trained ophthalmologist, Dr Matheos was awarded the Arthur Thomas Paterson Scholarship from the University of Auckland
Staff reporters1 min read
Productivity-enhancing smart glasses
Lenovo has introduced new smart glasses, Think Reality A3, offering productivity boosting technology to enable smarter workers in businesses big and small. “The A3 is a next generation augmented
Staff reporters1 min read